Get the Stockscreener App
65.14
0.65%
0.42
After Hours:
65.14
Mirum Pharmaceuticals Inc stock is traded at $65.14, with a volume of 1.11M.
It is up +0.65% in the last 24 hours and up +23.70% over the past month.
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.
See More
Previous Close:
$64.72
Open:
$65
24h Volume:
1.11M
Relative Volume:
2.31
Market Cap:
$3.27B
Revenue:
$379.25M
Net Income/Loss:
$-77.34M
P/E Ratio:
-40.40
EPS:
-1.6122
Net Cash Flow:
$-27.87M
1W Performance:
+22.01%
1M Performance:
+23.70%
6M Performance:
+28.48%
1Y Performance:
+58.53%
1-Day Range:
$64.07
$65.98
1-Week Range:
$54.74
$67.45
52-Week Range:
$36.86
$67.45
Mirum Pharmaceuticals Inc Stock (MIRM) Company Profile
Name
Mirum Pharmaceuticals Inc
Sector
Industry
Phone
650-667-4085
Address
989 EAST HILLSDALE BOULEVARD, SUITE 300, FOSTER CITY
Compare MIRM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MIRM
Mirum Pharmaceuticals Inc
|
65.14 | 3.25B | 379.25M | -77.34M | -27.87M | -1.6122 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.92 | 99.42B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.55 | 58.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.52 | 56.35B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
646.60 | 39.02B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
307.51 | 34.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Mirum Pharmaceuticals Inc Stock (MIRM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-11-25 | Resumed | Stifel | Buy |
| May-19-25 | Resumed | H.C. Wainwright | Buy |
| Apr-17-24 | Initiated | Stifel | Buy |
| Dec-18-23 | Reiterated | H.C. Wainwright | Buy |
| Nov-20-23 | Resumed | JP Morgan | Overweight |
| Nov-13-23 | Initiated | Morgan Stanley | Overweight |
| Oct-24-23 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-17-23 | Resumed | Evercore ISI | Outperform |
| Sep-20-23 | Initiated | JMP Securities | Mkt Outperform |
| Sep-01-22 | Initiated | Citigroup | Buy |
| Sep-20-21 | Initiated | JP Morgan | Overweight |
| Aug-07-20 | Upgrade | Raymond James | Outperform → Strong Buy |
| Aug-03-20 | Initiated | H.C. Wainwright | Buy |
| Jul-31-20 | Initiated | Piper Sandler | Overweight |
| Jun-25-20 | Initiated | Robert W. Baird | Outperform |
| Aug-12-19 | Initiated | Citigroup | Buy |
| Aug-12-19 | Initiated | Evercore ISI | Outperform |
| Aug-12-19 | Initiated | Guggenheim | Buy |
| Aug-12-19 | Initiated | ROTH Capital | Buy |
| Aug-12-19 | Initiated | Raymond James | Outperform |
View All
Mirum Pharmaceuticals Inc Stock (MIRM) Latest News
Mirum Pharma CEO Peetz sells $2.48 million in shares By Investing.com - Investing.com Canada
Mirum Pharma CFO Eric Bjerkholt sells $524k in stock By Investing.com - Investing.com Canada
Mirum Pharmaceuticals (NASDAQ:MIRM) Price Target Raised to $89.00 at Evercore ISI - MarketBeat
Mirum Pharmaceuticals Inc. Breaks Losing Streak — Is the Trend ReversingReal Trader Watchlist of Hot Stocks Released - 선데이타임즈
Is Mirum Pharmaceuticals Inc. forming bullish engulfing patternsBest 5x Return Trade Entries - thegnnews.com
Stifel Initiates Mirum Pharmaceuticals(MIRM.US) With Buy Rating, Announces Target Price $89 - 富途牛牛
Mirum's Meteoric Surge: What's Fueling the 9.38% Intraday Rally? - AInvest
HC Wainwright Issues Positive Forecast for Mirum Pharmaceuticals (NASDAQ:MIRM) Stock Price - MarketBeat
Mirum’s Financial Rocket: Soaring Figures, Intriguing Questions - StocksToTrade
Mirum Soars 10% on Analyst Upgrades and Pipeline Catalysts: Is This the Start of a Biotech Breakout? - AInvest
Analysts Just Shipped A Substantial Upgrade To Their Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Estimates - simplywall.st
Mirum Pharmaceuticals: Q2 Results Continues To Show Positive Momentum (NASDAQ:MIRM) - Seeking Alpha
Stifel resumes Mirum Pharmaceuticals stock coverage with Buy rating By Investing.com - Investing.com Canada
Mirum Pharmaceuticals Delivers Growth With Orphan Liver Drug Success - Finimize
MIRM Stock Up on Q2 Earnings and Revenue Beat, Raised 2025 View - MSN
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Q2 2025 Earnings Call Transcript - MSN
Insider Selling at Mirum Pharmaceuticals: A Signal of Confidence or Caution for Long-Term Investors? - AInvest
A Quick Look at Today's Ratings for Mirum Pharmaceuticals(MIRM.US), With a Forecast Between $66 to $89 - 富途牛牛
BioLife Solutions: HC Wainwright Raises PT to $32, Maintains Buy Rating - AInvest
Mirum Pharmaceuticals price target raised to $82 from $77 at Raymond James - TipRanks
Mirum Pharmaceuticals Reports Strong Q2 Growth and Raises Guidance - TipRanks
Mirum Pharmaceuticals Raises Revenue Guidance, Secures Reimbursement in Japan, and Expands Product Portfolio - AInvest
Citizens JMP Raises Mirum Pharmaceuticals Price Target to $81, Maintains Outperform Rating - AInvest
MIRM Stock Flying High: Too Late to Buy? - StocksToTrade
Mirum Pharmaceuticals shares rise 12.83% intraday after reporting strong Q2 results and raising 2025 guidance. - AInvest
MIRM Stock Up On Q2 Earnings And Revenue Beat, Raised 2025 View - Barchart.com
Mirum Pharmaceuticals price target raised to $81 from $79 at Citizens JMP - TipRanks
Mirum Soars 10.5% on Earnings Beat and Revenue Surge: A Biotech Breakout in the Making? - AInvest
Mirum Pharmaceuticals stock hits all-time high at 55.25 USD By Investing.com - Investing.com Australia
Mirum Pharmaceuticals stock hits all-time high at 55.25 USD - Investing.com
Mirum: JMP Securities Raises PT to $81, Maintains Market Outperform - AInvest
Mirum:Raymond James raises PT to $82, maintains Strong Buy rating. - AInvest
Mirum Pharmaceuticals stock price target raised to $80 from $73 at H.C. Wainwright - Investing.com Canada
Mirum Pharmaceuticals price target raised to $80 from $73 at H.C. Wainwright - TipRanks
Mirum:HC Wainwright Raises PT to $80, Maintains Buy Rating - AInvest
Mirum Pharmaceuticals stock price target raised to $81 by JMP - Investing.com South Africa
Mirum 2025 Q2 Earnings Losses Narrow Significantly - AInvest
Earnings call transcript: Mirum Pharmaceuticals sees revenue boost in Q2 2025 - Investing.com
Mirum Pharmaceuticals Q2 2025 Earnings Call Transcript - MarketBeat
Mirum Pharmaceuticals Reports Strong Q2 2025 Growth - TipRanks
Mirum Pharmaceuticals Q2 2025: Unpacking Contradictions on Market Penetration, Sales Growth, and Clinical Strategy - AInvest
Mirum Pharmaceuticals Reports Q2 2025 Earnings and Business Update - AInvest
Mirum Pharmaceuticals, Inc. (MIRM) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance
Mirum Pharmaceuticals soars as revenue crushes estimates - Investing.com
Mirum Pharmaceuticals earnings beat by $0.21, revenue topped estimates - Investing.com Canada
Mirum Pharmaceuticals reports Q2 EPS (12c), consensus (33c) - TipRanks
Earnings Flash (MIRM) Mirum Pharmaceuticals, Inc. Reports Q2 Revenue $127.8M, vs. FactSet Est of $108.1M - MarketScreener
Mirum Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update - Business Wire
Mirum Pharmaceuticals Q2 2025 Earnings Preview: EPS Estimate $-0.33, Revenue Estimate $108.1M. - AInvest
Traders Consider Averaging Down in Mirum Pharmaceuticals Inc.Community Verified Stock Suggestions Drive Volume - metal.it
Is Mirum Pharmaceuticals Inc. a growth stock or a value stockStay informed with expert market forecasts - Jammu Links News
Mirum Pharmaceuticals Inc Stock (MIRM) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.67%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):